Longterm effectiveness of herpes zoster vaccine among patients with autoimmune and inflammatory diseases

Huifeng Yun; Fenglong Xie; John W. Baddley; Kevin Winthrop; Kenneth G. Saag; Jeffrey R. Curtis

doi:10.3899/jrheum.160685

Longterm effectiveness of herpes zoster vaccine among patients with autoimmune and inflammatory diseases

Huifeng Yun, Fenglong Xie, John W. Baddley, Kevin Winthrop, Kenneth G. Saag, Jeffrey R. Curtis

School Of Public Health

Research output: Contribution to journal › Article › peer-review

27 Scopus citations

Abstract

Objective. The protection duration of herpes zoster (HZ) vaccination is unclear among patients with autoimmune (AI) diseases. Methods. Using 2006-2013 Medicare data, HZ vaccinated patients with AI were matched 1:2 to unvaccinated HZ. Incidence rates (IR) and adjusted risk ratios over time were calculated using Poisson regression. Results. Of 59,627 vaccinated patients, crude IR increased from 0.75/100 person-years during the first year post-vaccination to 1.25 during the seventh year. Vaccinated patients had a significantly lower risk of HZ compared with the unvaccinated through 5 years. Conclusion. HZ vaccination was significantly protective only for about 5 years among patients with AI.

Original language	English (US)
Pages (from-to)	1083-1087
Number of pages	5
Journal	Journal of Rheumatology
Volume	44
Issue number	7
DOIs	https://doi.org/10.3899/jrheum.160685
State	Published - Jul 1 2017

Keywords

Autoimmune diseases
Herpes zoster
Infection
Vaccination

ASJC Scopus subject areas

Rheumatology
Immunology and Allergy
Immunology

Access to Document

10.3899/jrheum.160685

Cite this

@article{a0fbd671efd84d21852e58cd9012ad52,

title = "Longterm effectiveness of herpes zoster vaccine among patients with autoimmune and inflammatory diseases",

abstract = "Objective. The protection duration of herpes zoster (HZ) vaccination is unclear among patients with autoimmune (AI) diseases. Methods. Using 2006-2013 Medicare data, HZ vaccinated patients with AI were matched 1:2 to unvaccinated HZ. Incidence rates (IR) and adjusted risk ratios over time were calculated using Poisson regression. Results. Of 59,627 vaccinated patients, crude IR increased from 0.75/100 person-years during the first year post-vaccination to 1.25 during the seventh year. Vaccinated patients had a significantly lower risk of HZ compared with the unvaccinated through 5 years. Conclusion. HZ vaccination was significantly protective only for about 5 years among patients with AI.",

keywords = "Autoimmune diseases, Herpes zoster, Infection, Vaccination",

author = "Huifeng Yun and Fenglong Xie and Baddley, {John W.} and Kevin Winthrop and Saag, {Kenneth G.} and Curtis, {Jeffrey R.}",

year = "2017",

month = jul,

day = "1",

doi = "10.3899/jrheum.160685",

language = "English (US)",

volume = "44",

pages = "1083--1087",

journal = "Journal of Rheumatology",

issn = "0315-162X",

publisher = "Journal of Rheumatology",

number = "7",

}

TY - JOUR

T1 - Longterm effectiveness of herpes zoster vaccine among patients with autoimmune and inflammatory diseases

AU - Yun, Huifeng

AU - Xie, Fenglong

AU - Baddley, John W.

AU - Winthrop, Kevin

AU - Saag, Kenneth G.

AU - Curtis, Jeffrey R.

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Objective. The protection duration of herpes zoster (HZ) vaccination is unclear among patients with autoimmune (AI) diseases. Methods. Using 2006-2013 Medicare data, HZ vaccinated patients with AI were matched 1:2 to unvaccinated HZ. Incidence rates (IR) and adjusted risk ratios over time were calculated using Poisson regression. Results. Of 59,627 vaccinated patients, crude IR increased from 0.75/100 person-years during the first year post-vaccination to 1.25 during the seventh year. Vaccinated patients had a significantly lower risk of HZ compared with the unvaccinated through 5 years. Conclusion. HZ vaccination was significantly protective only for about 5 years among patients with AI.

AB - Objective. The protection duration of herpes zoster (HZ) vaccination is unclear among patients with autoimmune (AI) diseases. Methods. Using 2006-2013 Medicare data, HZ vaccinated patients with AI were matched 1:2 to unvaccinated HZ. Incidence rates (IR) and adjusted risk ratios over time were calculated using Poisson regression. Results. Of 59,627 vaccinated patients, crude IR increased from 0.75/100 person-years during the first year post-vaccination to 1.25 during the seventh year. Vaccinated patients had a significantly lower risk of HZ compared with the unvaccinated through 5 years. Conclusion. HZ vaccination was significantly protective only for about 5 years among patients with AI.

KW - Autoimmune diseases

KW - Herpes zoster

KW - Infection

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=85021830171&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021830171&partnerID=8YFLogxK

U2 - 10.3899/jrheum.160685

DO - 10.3899/jrheum.160685

M3 - Article

C2 - 28298565

AN - SCOPUS:85021830171

SN - 0315-162X

VL - 44

SP - 1083

EP - 1087

JO - Journal of Rheumatology

JF - Journal of Rheumatology

IS - 7

ER -

Longterm effectiveness of herpes zoster vaccine among patients with autoimmune and inflammatory diseases

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this